BioSpace News Archive

Revance Therapeutics, Inc., a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago.

Immunome, Inc. today announced updates to the ongoing development of its lead oncology program, IMM-ONC-01, a novel immuno-oncology agent that inhibits IL-38, an immunosuppressive cytokine.

Nanomix Corporation, a leader in the development of mobile, affordable, point-of-care diagnostics, is pleased to announce that it has upgraded to the OTCQB® Venture Market, and will continue to trade under the symbol NNMX.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced it has signed a second, exclusive research agreement with the Queensland University of Technology (QUT), Australia.

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferences.

TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Kuick Research has recognized the Company as a key player in the gamma-delta T cell therapy market.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA ® (valbenazine) capsules for the treatment of tardive dyskinesia (TD) at the American Psychiatric Association (APA) Annual Meeting being held in person May 21-25 in New Orleans and virtually June 7-10 .

The National Comprehensive Cancer Network® announced the recipients of 2022 awards for both internal and external champions advancing NCCN’s mission and helping all people with cancer to live better lives.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that Bentrio has been approved by the Philippines’ Food and Drug Administration (FDA) and is now cleared for commercialization in that country of 115 million people.